Buy 3 High-Flying AI-Powered EMS Stocks for 2H Amid Solid Demand

Zacks highlights Celestica, Jabil and Sanmina as top EMS beneficiaries of AI, cloud infrastructure, EVs and AI-led medical devices, with all three carrying Zacks Rank #2 (Buy). The article cites strong expected current-year growth for Celestica (revenue 53.8%, earnings 67.9%), Jabil (14.2%, 27.7%) and Sanmina (75.5%, 85.8%), along with improving consensus estimates. While broadly positive for the three stocks and the EMS group, this is mostly a bullish analyst commentary piece rather than new company-specific news.

Analysis

The real trade here is not “AI exposure” in the abstract; it is a tightening of the advanced hardware supply chain where hyperscaler capex, optical networking, and factory automation are converging. CLS looks like the cleanest pure-play beneficiary of incremental 800G/400G switch cycles, while SANM has the most asymmetric operating leverage if cloud/communications programs convert from pipeline to production over the next 2-4 quarters. JBL sits between them as the more diversified, lower-volatility compounder, which likely makes it the institutional parking spot if AI spend broadens but doesn’t accelerate.

Second-order winners are the suppliers of high-speed interconnects, precision tooling, and test/inspection equipment, because every additional rack deployed increases complexity downstream. The likely losers are smaller EMS players with weaker design-in capabilities and less global procurement scale; in a world of supply-chain fragmentation and tariff risk, buyers will keep consolidating volume toward vendors that can co-locate engineering, sourcing, and final assembly. That dynamic can extend gross margin expansion beyond the headline revenue growth if these names maintain pricing discipline.

The market is probably underestimating cyclicality risk in a segment that looks secularly strong on the surface. If hyperscaler capex pauses for even one budget cycle, the multiple compression can be sharp because investors are currently paying for uninterrupted 2026/27 growth visibility; these are not “safe” growth stocks, they are execution-sensitive industrial tech names. The key reversal signal is not macro recession alone, but a deceleration in order cadence or delayed program ramps, which would show up first in estimates and backlog commentary over the next 1-2 quarters.

Key Decisions for Investors

• Go long CLS on any 3-5% pullback over the next 1-2 weeks; target a continuation trade into the next estimate revision window, with a stop if hyperscaler capex commentary softens. Risk/reward favors 2:1+ if 800G/400G demand remains tight.
• Use JBL as the core long versus the group for a 3-6 month hold; it is the best relative-quality expression if AI-related demand broadens but becomes choppier. Consider it the lower-volatility leg in a basket with CLS/SANM.
• Pair trade: long SANM / short a weaker-capitalized EMS peer or industrial tech proxy if available, betting that end-to-end supply chain integration wins share as customers de-risk supply chains. Hold 2-4 quarters; thesis breaks if cloud/communications bookings fail to convert.
• For tactical upside, buy medium-dated call spreads in CLS or SANM after any post-earnings consolidation. Use defined risk because these names can re-rate down quickly if estimate momentum stalls.
• Avoid chasing the basket indiscriminately after a multi-month run; wait for estimate revisions to confirm. The asymmetric entry is on a dip, not on breakout highs, because the valuation support depends on sustained upward revisions.